SelectScience InterviewsClinical Diagnostics
Advancing Alzheimer’s diagnostics at Quanterix with multi-marker testing
Exploring the next phase of Alzheimer’s diagnostics from AAIC 2026
Exploring the next phase of Alzheimer’s diagnostics from AAIC 2026
AAIC 2026 interview with Beckman Coulter Diagnostics
How new diagnostic approaches could help clinicians identify, triage, and monitor patients earlier and more effectively
How neurology biomarkers are moving from CSF and PET into accessible blood tests for Alzheimer’s disease and neurodegenerative disease care
Advancing Alzheimer's disease research with innovative plasma Tau biomarkers and automated, high-throughput assay workflows
At AAIC 2026, Dr. Ashton Harper, Roche Diagnostics, discusses how pTau217 could help reshape Alzheimer’s testing across primary and secondary care